Dennis Calvert Interview with Kenny Polcari

BioLargo's President and CEO Dennis P. Calvert sat down for an interview with Kenny Polcari, renowned finance and investor intelligence expert and financial commentator for Fox News, CNBC, and CNN, and more. In this interview, Dennis does a deep dive on what's driving BioLargo's growth, including expanded rollout of Pooph pet odor control products in Walmart stores across the country, the commercial launch of the company's PFAS technology, and its newly acquired sodium-sulfur battery energy storage technology.

Watch the full interview here:

About Kenny Polcari

Polcari is currently the Managing Partner of Kace Capital Advisors, Chief Market Strategist at SlateStone Wealth, sits on the Advisory Board of The Headstrong Project, and is a member of the National Organization of Investment Professionals. He is a Fox Business, CNBC, and CNN financial commentator. He started his career on the floor of the New York Stock Exchange as an institutional broker starting in 1985 and graduated from Boston University, School of Management in 1983 with a Bachelor of Science in Business Administration with a concentration in Finance.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.  

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.